Shining a light in the black box of orphan drug pricing
Open Access
- 1 January 2014
- journal article
- Published by Springer Science and Business Media LLC in Orphanet Journal of Rare Diseases
- Vol. 9 (1), 62
- https://doi.org/10.1186/1750-1172-9-62
Abstract
The pricing mechanism of orphan drugs appears arbitrary and has been referred to as a "black box". Therefore, the aim of this study is to investigate how drug- and disease-specific variables relate to orphan drug prices. Additionally, we aim to explore if certain country-specific pricing and reimbursement policies affect the price level of orphan drugs. Annual treatment costs per indication per patient were calculated for 59 orphan drugs with a publicly available price in Belgium, the Netherlands, Czech Republic, France, Italy and the United Kingdom. A multiple linear regression model was built with 14 drug- and disease-specific variables. A Mann-Whitney U test was used to explore whether there is a correlation between annual treatment costs of orphan drugs across countries with different pricing and reimbursement policies. Repurposed orphan drugs, orally administered orphan drugs or orphan drugs for which an alternative treatment is available are associated with lower annual treatment costs. Orphan drugs with multiple orphan indications, for chronic treatments or for which an improvement in overall survival or quality-of-life has been demonstrated, are associated with higher annual treatment costs. No association was found between annual treatments cost of orphan drugs across countries and the different pricing and reimbursement systems. This study has shown that prices of orphan drugs are influenced by factors such as the availability of an alternative drug treatment, repurposing, etc. Current debate about the affordability of orphan drugs highlights the need for more transparency in orphan drug price setting.Keywords
This publication has 30 references indexed in Scilit:
- Sustainable rare diseases business and drug access: no time for misconceptionsOrphanet Journal of Rare Diseases, 2013
- The weight of nations: an estimation of adult human biomassBMC Public Health, 2012
- Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?Orphanet Journal of Rare Diseases, 2012
- Estimating the budget impact of orphan medicines in Europe: 2010 - 2020Orphanet Journal of Rare Diseases, 2011
- The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseasesOrphanet Journal of Rare Diseases, 2011
- Pricing and reimbursement of orphan drugs: the need for more transparencyOrphanet Journal of Rare Diseases, 2011
- A comparative study of European rare disease and orphan drug marketsHealth Policy, 2010
- The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?Health Policy, 2010
- Extraordinary Pricing of Orphan Drugs: Is it a Socially Responsible Strategy for the U.S. Pharmaceutical Industry?Journal of Business Ethics, 2009
- Geometric method for measuring body surface area: A height-weight formula validated in infants, children, and adultsThe Journal of Pediatrics, 1978